The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
Open accessAbstract
In a phase I study of autologous chimeric antigen receptor (CAR) anti-LeY T-cell therapy of acute myeloid leukemia (AML), we examined the safety and postinfusion persistence of adoptively transferred T cells. Following fludarabine-containing preconditioning, four patients received up to 1.3 × 109 total T cells, of which 14-38% expressed the CAR. Grade 3 or 4 toxicity was not observed. One patient achieved a cytogenetic remission whereas another with active leukemia had a reduction in peripheral blood (PB) blasts and a third showed a protracted remission. Using an aliquot of In111-labeled CAR T cells, we demonstrated trafficking to the bone marrow (BM) in those patients with the greatest clinical benefit. Furthermore, in a patient with leukemia cutis, CAR T cells infiltrated proven sites of disease. Serial PCR of PB and BM for the LeY transgene demonstrated that infused CAR T cells persisted for up to 10 months. Our study supports the feasibility and safety of CAR-T-cell therapy in high-risk AML, and demonstrates durable in vivo persistence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Self-citationHuman T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675
Targeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., Lindgren, C. G., Lin, Y., Pagel, J. M., Budde, L. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387969 · Cited by 529
Pulè, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 487
Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 407
Zhang, S., Zhang, H. S., Cordon-Cardo, C., Reuter, V. E., Singhal, A. K., Lloyd, K. O., & Livingston, P. O. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970926)73:1<50::aid-ijc9>3.0.co;2-0 · Cited by 299
Hwu, P., Shafer, G. E., Treisman, J., Schindler, D. G., Gross, G., Cowherd, R., Rosenberg, S. A., & Eshhar, Z. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.1.361 · Cited by 256
Sakamoto, J., Furukawa, K., Cordon‐Cardo, C., Yin, B. W. T., Rettig, W. J., Oettgen, H. F., Old, L. J., & Lloyd, K. O. (1986) · PubMed · Cited by 230
Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
Stancovski, I., Schindler, D. G., Waks, T., Yarden, Y., Sela, M., & Eshhar, Z. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.11.6577 · Cited by 216
Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.
Moritz, D., Wels, W., Mattern, J., & Groner, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4318 · Cited by 208
Haynes, N. M., Trapani, J. A., Teng, M. W. L., Jackson, J. T., Cerruti, L., Jane, S. M., Kershaw, M. H., Smyth, M. J., & Darcy, P. K. (2002) · Blood · doi:10.1182/blood-2002-04-1041 · Cited by 197
Self-citationGupta, V., Tallman, M. S., & Weisdorf, D. J. (2011) · Blood · doi:10.1182/blood-2010-10-265603 · Cited by 178
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
Saenger, Y. M., & Wolchok, J. D. (2008) · PubMed Central · Cited by 164
Wen, Y.-J., Min, R., Tricot, G. J. K., Barlogie, B., & Yi, Q. (2002) · Blood · doi:10.1182/blood.v99.9.3280 · Cited by 151
Westwood, J. A., Smyth, M. J., Teng, M. W. L., Moeller, M., Trapani, J. A., Scott, A. M., Smyth, F. E., Cartwright, G. A., Power, B. E., Hönemann, D., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504312102 · Cited by 148
Self-citationThe Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
Lee, D. W., Barrett, D. M., Mackall, C. L., Orentas, R. J., & Grupp, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1920 · Cited by 128
Peinert, S., Prince, H. M., Guru, P., Kershaw, M. H., Smyth, M. J., Trapani, J. A., Gambell, P. C., Harrison, S. J., Scott, A. M., Smyth, F. E., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.21 · Cited by 118
Self-citationDual-specific T cells combine proliferation and antitumor activity
Kershaw, M. H., Westwood, J. A., & Hwu, P. (2002) · Nature Biotechnology · doi:10.1038/nbt756 · Cited by 114
Self-citationCoinhibitory molecules in hematologic malignancies: targets for therapeutic intervention
Norde, W. J., Hobo, W. A., van der Voort, R., & Dolstra, H. (2012) · Blood · doi:10.1182/blood-2012-02-412510 · Cited by 78
Kobayashi, K., Sakamoto, J., Kito, T., Yamamura, Y., Koshikawa, T., Fujita, M., Watanabe, T., & Nakazato, H. (1993) · PubMed · Cited by 75
Lamers, C. H. J., Willemsen, R. A., Luider, B. A., et al. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700477 · Cited by 73
Burns, W. R., Zheng, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · Blood · doi:10.1182/blood-2009-01-199216 · Cited by 70
Expansion and Characterization of T Cells Transduced with a Chimeric Receptor against Ovarian Cancer
Parker, L. L., Do, M. T., Westwood, J. A., Wunderlich, J. R., Dudley, M. E., Rosenberg, S. A., & Hwu, P. (2000) · Human Gene Therapy · doi:10.1089/104303400750038480 · Cited by 55
Self-citationNeeson, P. J., Shin, A., Tainton, K. M., Guru, P., Prince, H. M., Harrison, S. J., Peinert, S., Smyth, M. J., Trapani, J. A., Kershaw, M. H., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.59 · Cited by 45
Self-citationIn Vivo Tracking of Dendritic Cells in Patients With Multiple Myeloma
Prince, H. M., Wall, D. M., Ritchie, D., Hönemann, D., Harrison, S. J., Quach, H., Thompson, M., Hicks, R. J., Lau, E. W. F., Davison, J., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815c5153 · Cited by 43
Self-citationHsing (1996) · doi:10.1002/(sici)1097-0215(19960208)65:4 · Cited by 1
Cited by
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
Gene-engineered T cells for cancer therapy
Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3565 · Cited by 505
Self-citation
Metadata
- Authors
- Ritchie, D. S., Neeson, P. J., Khot, A., Peinert, S., Tai, T., Tainton, K., Chen, K., Shin, M., Wall, D. M., Hönemann, D., Gambell, P., Westerman, D. A., Haurat, J., Westwood, J. A., Scott, A. M., Kravets, L., Dickinson, M., Trapani, J. A., Smyth, M. J., Darcy, P. K., Kershaw, M. H., & Prince, H. M.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 21
- Issue
- 11
- Pages
- 2122-2129
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2014751400
- Cited by
- 443
- References
- 36
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.